A drug company said Friday that a medicine it sells to tamp down inflammation has helped prevent the need for breathing machines in hospitalized COVID-19 patients in the first large study that primarily enrolled Hispanics and Blacks.
Switzerland-based Roche reported the results for tocilizumab, sold now as Actemra and RoActemra for treating rheumatoid arthritis and some other diseases. The company said it would quickly publish the results, which have not yet been reviewed by independent scientists, and would speak with regulators about next steps.
Looked at separately, there were fewer deaths among those on the drug — 8.6% versus 10.4% on placebo — but the difference was too small to say it might not have been due to chance.
It’s unclear how the results will be viewed; another drug that works in a similar way failed in an experiment rigorously testing it in COVID-19 patients but some less scientific, observational studies have suggested benefit.
This is the third time this week that companies have announced positive results from studies testing COVID treatments via press releases. Companies often are required to disclose results that could affect their financial situation.
On Monday, Eli Lilly reported benefits from a study testing its anti-inflammatory drug baricitinib when combined with the antiviral drug remdesivir. On Wednesday, it said interim results from very early testing suggested that its experimental antibody drug showed promise for helping clear the virus and possibly reducing the need for hospitalization in mild to moderately ill patients.